Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.
|Videos|June 11, 2019
Dr. Daniel George on the Treatment Landscape for RCC
Author(s)Daniel George, MD
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Advertisement
Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Advertisement
Related to this article
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5